Antihypertensive Dosing Trials Could Have Three-Arm, No-Placebo Design
Executive Summary
Antihypertensive drug trials incorporating three dose-ranging arms and no placebo group would give a better picture of a drug's entire dose-response relationship than current fixed-dose studies, FDA Cardio-Renal Drug Products Director Raymond Lipicky, MD, told FDA's Cardiovascular & Renal Drugs Advisory Committee.